Big Pharma's AI Arms Race: Why Novo Nordisk Just Bet on Claude
Novo Nordisk just added Anthropic's Claude Science to an AI drug discovery stack that already includes OpenAI. Here's what the deal reveals about AI in healthcare.
AI Designed a Drug That Made Six Ageing Clocks Run Backwards
An AI-discovered, AI-designed drug lowered predicted biological age across six independent ageing clocks in a phase 2a trial. What it means, and what it doesn't.
The End of the Ageing Clock? How AI Learned to Reason About Getting Old
AI in 2026 is moving past ageing clocks that spit out a single number towards foundation models that reason about biological age, predict disease and nominate targets. Here is what changed and why it matters.
AI Can Write a Virus's Genome. It Still Can't Read One
Scientists mutated every letter of the ΦX174 phage genome and measured the result. Top AI models predicted it only moderately well, a reality check for AI biology.
AI Beat the Lab at Antibody Design, But Just Once
The first blinded, wet-lab-validated benchmark for AI antibody design just landed in Nature Biotechnology. Here is what the models got right, and wrong.
A Nobel Laureate's AI Just Tried to Simulate a Whole Human Cell
GenBio AI's AIDO Cell is a 'world model' that simulates a human cell across scales, from DNA to shape. Here's what it does, why it matters, and what still needs proving.
AI Discovered a Novel Drug Target; and Pharma Bought It
Genentech validated the first AI-discovered neuroscience drug target from its $12B Recursion partnership. A proof point the AI-drug discovery field needed.
Evolution as Training Data: How Biohub's Open Protein World Model Is Rewiring Drug Discovery
Biohub's open-source ESM models learned the rules of protein biology from evolution alone — and designed working drug binders in days. Here's what the release means, and where it falls short.
AI Drug Discovery's Moment of Truth: A $2.75B Bet, Zero Approvals, and the Drug That Could Change Both
Eli Lilly just wagered up to $2.75 billion on AI-designed medicines, yet not one AI-discovered drug has full FDA approval. Here's why 2026 is the year the field finally gets tested against clinical reality.
The First AI-Designed Drug Just Entered Phase III. Here's What That Actually Proves.
Insilico Medicine has pushed rentosertib, a drug whose target and molecule were both generated by AI, into a pivotal Phase III trial. It's the clearest test yet of whether AI drug discovery can produce medicines that work, not just headlines.
Ebola's 100-Day Test: The Bundibugyo Vaccine Sprint
The Bundibugyo Ebola outbreak is now the largest in DRC history. With no licensed vaccine, three candidates have reached human trials in weeks — a real-world stress test of the 100 Days Mission, AI-assisted drug discovery and outbreak modelling.